CLEC9A and neoplasm: Here, we show that the CLEC9A product, DNGR-1, can promote cross-presentation of dead tumor cell antigens leading to anti-tumor immunity but that this effect is often masked by sGSN produced either locally in the TME or circulating in plasma.